170 related articles for article (PubMed ID: 28741405)
1. Optimized tPA: A non-neurotoxic fibrinolytic agent for the drainage of intracerebral hemorrhages.
Goulay R; Naveau M; Gaberel T; Vivien D; Parcq J
J Cereb Blood Flow Metab; 2018 Jul; 38(7):1180-1189. PubMed ID: 28741405
[TBL] [Abstract][Full Text] [Related]
2. Addition of intravenous N-methyl-D-aspartate receptor antagonists to local fibrinolytic therapy for the optimal treatment of experimental intracerebral hemorrhages.
Thiex R; Weis J; Krings T; Barreiro S; Yakisikli-Alemi F; Gilsbach JM; Rohde V
J Neurosurg; 2007 Feb; 106(2):314-20. PubMed ID: 17410717
[TBL] [Abstract][Full Text] [Related]
3. The role of endogenous versus exogenous tPA on edema formation in murine ICH.
Thiex R; Mayfrank L; Rohde V; Gilsbach JM; Tsirka SA
Exp Neurol; 2004 Sep; 189(1):25-32. PubMed ID: 15296833
[TBL] [Abstract][Full Text] [Related]
4. Fibrinolysis therapy achieved with tissue plasminogen activator and aspiration of the liquefied clot after experimental intracerebral hemorrhage: rapid reduction in hematoma volume but intensification of delayed edema formation.
Rohde V; Rohde I; Thiex R; Ince A; Jung A; Dückers G; Gröschel K; Röttger C; Küker W; Müller HD; Gilsbach JM
J Neurosurg; 2002 Oct; 97(4):954-62. PubMed ID: 12405387
[TBL] [Abstract][Full Text] [Related]
5. Urokinase, a promising candidate for fibrinolytic therapy for intracerebral hemorrhage.
Tan Q; Chen Q; Niu Y; Feng Z; Li L; Tao Y; Tang J; Yang L; Guo J; Feng H; Zhu G; Chen Z
J Neurosurg; 2017 Feb; 126(2):548-557. PubMed ID: 27104852
[TBL] [Abstract][Full Text] [Related]
6. Suppression of NLRP3 attenuates hemorrhagic transformation after delayed rtPA treatment in thromboembolic stroke rats: Involvement of neutrophil recruitment.
Guo Z; Yu S; Chen X; Zheng P; Hu T; Duan Z; Liu X; Liu Q; Ye R; Zhu W; Liu X
Brain Res Bull; 2018 Mar; 137():229-240. PubMed ID: 29258866
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of fibrinolytic properties of Alteplase, Tenecteplase and Urokinase in an in vitro clot model of intracerebral haemorrhage.
Keric N; Döbel M; Krenzlin H; Kurz E; Tanyildizi Y; Heimann A; König J; Kempski O; Ringel F; Masomi-Bornwasser J
J Stroke Cerebrovasc Dis; 2020 Sep; 29(9):105073. PubMed ID: 32807475
[TBL] [Abstract][Full Text] [Related]
8. O2L-001, an innovative thrombolytic to evacuate intracerebral haematoma.
Thiebaut AM; Louet ER; Ianszen M; Guichard MJ; Hanley DF; Gaudin C; Parcq J
Brain; 2023 Nov; 146(11):4690-4701. PubMed ID: 37450572
[TBL] [Abstract][Full Text] [Related]
9. Urokinase versus Alteplase for intraventricular hemorrhage fibrinolysis.
Gaberel T; Montagne A; Lesept F; Gauberti M; Lemarchand E; Orset C; Goulay R; Bertrand T; Emery E; Vivien D
Neuropharmacology; 2014 Oct; 85():158-65. PubMed ID: 24846802
[TBL] [Abstract][Full Text] [Related]
10. Ultra-early clot aspiration after lysis with tissue plasminogen activator in a porcine model of intracerebral hemorrhage: edema reduction and blood-brain barrier protection.
Wagner KR; Xi G; Hua Y; Zuccarello M; de Courten-Myers GM; Broderick JP; Brott TG
J Neurosurg; 1999 Mar; 90(3):491-8. PubMed ID: 10067918
[TBL] [Abstract][Full Text] [Related]
11. The long-term effect of recombinant tissue-plasminogen-activator (rt-PA) on edema formation in a large-animal model of intracerebral hemorrhage.
Thiex R; Küker W; Müller HD; Rohde I; Schröder JM; Gilsbach JM; Rohde V
Neurol Res; 2003 Apr; 25(3):254-62. PubMed ID: 12739233
[TBL] [Abstract][Full Text] [Related]
12. Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial.
Morgan T; Zuccarello M; Narayan R; Keyl P; Lane K; Hanley D
Acta Neurochir Suppl; 2008; 105():147-51. PubMed ID: 19066101
[TBL] [Abstract][Full Text] [Related]
13. Management of delayed edema formation after fibrinolytic therapy for intracerebral hematomas: preliminary experimental data.
Rohde V; Uzma N; Thiex R; Samadani U
Acta Neurochir Suppl; 2008; 105():101-4. PubMed ID: 19066092
[TBL] [Abstract][Full Text] [Related]
14. Future perspectives on the fibrinolytic therapy of intracerebral hemorrhages.
Thiex R
Cent Nerv Syst Agents Med Chem; 2011 Jun; 11(2):150-6. PubMed ID: 21521167
[TBL] [Abstract][Full Text] [Related]
15. Intraventricular fibrinolysis does not increase perihemorrhagic edema after intracerebral hemorrhage.
Volbers B; Wagner I; Willfarth W; Doerfler A; Schwab S; Staykov D
Stroke; 2013 Feb; 44(2):362-6. PubMed ID: 23306318
[TBL] [Abstract][Full Text] [Related]
16. No exacerbation of perihematomal edema with intraventricular tissue plasminogen activator in patients with spontaneous intraventricular hemorrhage.
Ziai W; Moullaali T; Nekoovaght-Tak S; Ullman N; Brooks JS; Morgan TC; Hanley DF
Neurocrit Care; 2013 Jun; 18(3):354-61. PubMed ID: 23463422
[TBL] [Abstract][Full Text] [Related]
17. The effect of monascin on hematoma clearance and edema after intracerebral hemorrhage in rats.
Wang J; Wang G; Yi J; Xu Y; Duan S; Li T; Sun XG; Dong L
Brain Res Bull; 2017 Sep; 134():24-29. PubMed ID: 28655601
[TBL] [Abstract][Full Text] [Related]
18. Tin-mesoporphyrin, a potent heme oxygenase inhibitor, for treatment of intracerebral hemorrhage: in vivo and in vitro studies.
Wagner KR; Hua Y; de Courten-Myers GM; Broderick JP; Nishimura RN; Lu SY; Dwyer BE
Cell Mol Biol (Noisy-le-grand); 2000 May; 46(3):597-608. PubMed ID: 10872746
[TBL] [Abstract][Full Text] [Related]
19. Single- and two- chain tissue type plasminogen activator treatments differentially influence cerebral recovery after stroke.
Anfray A; Brodin C; Drieu A; Potzeha F; Dalarun B; Agin V; Vivien D; Orset C
Exp Neurol; 2021 Apr; 338():113606. PubMed ID: 33453214
[TBL] [Abstract][Full Text] [Related]
20. Hematoma expansion in experimental intracerebral hemorrhage is not altered by peracute treatment with recombinant tissue plasminogen activator.
Pfeilschifter W; Kashefiolasl S; Lauer A; Steinmetz H; Foerch C
Neuroscience; 2013 Oct; 250():181-8. PubMed ID: 23856067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
